NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Document | Date |
|---|---|
| Quarterly results · Q1 FY27 LASA SUPERGENERICS LIMITED – Q1 FY2026-27 SUMMARY HEADLINE NUMBERS • Company is LASA Supergenerics Limited (BSE: 540702, NSE: LASA), a pharmaceutica | 2026-08-14 |
| Quarterly results · Q4 FY26 LASA SUPERGENERICS LIMITED – FINANCIAL SUMMARY Quarter & Year Ended March 31, 2026 --- HEADLINE NUMBERS • Total Assets: Rs. 6,627.18 lakhs (down fr | 2026-05-29 |
| Quarterly results · Q3 FY26 LASA SUPERGENERICS LIMITED – Q3 FY2025-26 SUMMARY HEADLINE NUMBERS • Unaudited Financial Results for quarter ended December 31, 2025 – Board approve | 2026-02-13 |
| Quarterly results · Q2 FY26 LASA SUPERGENERICS LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Net Loss Before Tax (H1 FY26): Rs. 2,821.93 lakhs • Total Assets (Sep 30, 2025): Rs | 2025-11-14 |
| Annual report FY2025 LASA SUPERGENERICS LIMITED – ANNUAL REPORT 2024-25 SUMMARY HEADLINE NUMBERS • Revenue from operations: Rs 14,244.81 lakhs (FY 2024-25) vs Rs 10,433. | 2025-09-05 |
| Quarterly results · Q1 FY26 LASA SUPERGENERICS LIMITED – Q1 FY2025-26 SUMMARY HEADLINE NUMBERS • Reporting Period: Quarter ended June 30, 2025 (Q1 FY2025-26) • Unaudited Financ | 2025-08-13 |
| Quarterly results | 2025-02-13 |
| Quarterly results | 2024-11-15 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lasa Supergenerics Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.